晚期宫颈癌-话题@MedSci

#晚期宫颈癌#

20篇内容 | 1521人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2204987, encodeId=9dfa220498e8d, content=<a href='/topic/show?id=196b9e808ed' target=_blank style='color:#2F92EE;'>#阿帕替尼#</a> <a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a> <a href='/topic/show?id=1f883652ea9' target=_blank style='color:#2F92EE;'>#卡瑞利珠单抗#</a>, objectTitle=CANCER COMMUN | 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌的长期生存结果及免疫检查点抑制剂再治疗研究, objectType=article, longId=826021, objectId=02d7826021d0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240516/1715826294614_92910.png, objectUrl=/article/show_article.do?id=02d7826021d0, replyNumber=0, likeNumber=75, createdTime=2024-05-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=02d7826021d0, moduleTitle=CANCER COMMUN | 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌的长期生存结果及免疫检查点抑制剂再治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02d7826021d0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1616421, encodeId=beee1616421ff, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, objectType=article, longId=302279, objectId=6eee3022e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eee3022e979, replyNumber=0, likeNumber=97, createdTime=2022-04-04, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eee3022e979, moduleTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eee3022e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616420, encodeId=61e11616420db, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, objectType=article, longId=299549, objectId=91b029954956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91b029954956, replyNumber=0, likeNumber=86, createdTime=2022-02-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91b029954956, moduleTitle=J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91b029954956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616419, encodeId=560e161641903, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=293023, objectId=5fe32930236d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fe32930236d, replyNumber=0, likeNumber=57, createdTime=2021-12-30, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fe32930236d, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fe32930236d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616418, encodeId=93ef1616418d0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, objectType=article, longId=292558, objectId=2c632925589c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c632925589c, replyNumber=0, likeNumber=80, createdTime=2021-12-24, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c632925589c, moduleTitle=J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c632925589c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616417, encodeId=b054161641e19, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, objectType=article, longId=217443, objectId=bacd21e4438e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacd21e4438e, replyNumber=0, likeNumber=66, createdTime=2021-09-24, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacd21e4438e, moduleTitle=Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacd21e4438e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616416, encodeId=14951616416fe, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=210992, objectId=3d082109924e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d082109924e, replyNumber=0, likeNumber=92, createdTime=2021-05-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d082109924e, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d082109924e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616415, encodeId=2ff2161641517, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, objectType=article, longId=202292, objectId=ae1420229214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae1420229214, replyNumber=0, likeNumber=76, createdTime=2020-10-21, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae1420229214, moduleTitle=J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae1420229214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616414, encodeId=2142161641445, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=191720, objectId=0445191e204e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0445191e204e, replyNumber=0, likeNumber=0, createdTime=2020-04-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0445191e204e, moduleTitle=Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0445191e204e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616413, encodeId=011816164131a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, objectType=article, longId=190021, objectId=dadc19002166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadc19002166, replyNumber=0, likeNumber=67, createdTime=2020-03-16, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadc19002166, moduleTitle=Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadc19002166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616412, encodeId=ee2a1616412e0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, objectType=article, longId=166719, objectId=4a10166e19ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a10166e19ca, replyNumber=0, likeNumber=76, createdTime=2019-05-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a10166e19ca, moduleTitle=LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a10166e19ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616411, encodeId=2f0b1616411d0, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志, objectType=article, longId=152333, objectId=397315233363, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397315233363, replyNumber=0, likeNumber=77, createdTime=2018-11-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397315233363, moduleTitle=CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397315233363)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616410, encodeId=505816164108a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告, objectType=article, longId=117280, objectId=ed8511e28047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed8511e28047, replyNumber=0, likeNumber=132, createdTime=2017-10-25, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed8511e28047, moduleTitle=Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed8511e28047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616409, encodeId=c1f6161640968, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？, objectType=article, longId=107569, objectId=880d10e56917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=880d10e56917, replyNumber=0, likeNumber=130, createdTime=2017-08-05, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=880d10e56917, moduleTitle=Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=880d10e56917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616408, encodeId=9e4b16164085b, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=49147, objectId=a38a4914ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38a4914ee9, replyNumber=0, likeNumber=131, createdTime=2015-04-10, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38a4914ee9, moduleTitle=里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38a4914ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616407, encodeId=5297161640e87, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌, objectType=article, longId=46416, objectId=13de46416c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13de46416c3, replyNumber=0, likeNumber=114, createdTime=2015-02-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13de46416c3, moduleTitle=The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13de46416c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616406, encodeId=f94216164066c, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, objectType=article, longId=43043, objectId=f21c43043db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21c43043db, replyNumber=0, likeNumber=127, createdTime=2014-11-26, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21c43043db, moduleTitle=罗氏Avastin再获批 **用于晚期宫颈癌的生物药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21c43043db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616405, encodeId=354116164052a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=JCO：提高晚期宫颈癌存活率的新疗法, objectType=article, longId=40836, objectId=87824083629, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87824083629, replyNumber=0, likeNumber=68, createdTime=2014-10-01, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87824083629, moduleTitle=JCO：提高晚期宫颈癌存活率的新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87824083629)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616404, encodeId=ff011616404ae, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, objectType=article, longId=39215, objectId=fcdb3921526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcdb3921526, replyNumber=0, likeNumber=67, createdTime=2014-08-20, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcdb3921526, moduleTitle=FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcdb3921526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1616403, encodeId=cfb216164031a, content=<a href='/topic/show?id=8a0f59823b2' target=_blank style='color:#2F92EE;'>#晚期宫颈癌#</a>, objectTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, objectType=article, longId=38730, objectId=486438e3037, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=486438e3037, replyNumber=0, likeNumber=80, createdTime=2014-08-08, rootId=0, userName=ms7258648636991762, userId=5a7b19750456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=486438e3037, moduleTitle=JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=486438e3037)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期宫颈癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#阿帕替尼# #晚期宫颈癌# #卡瑞利珠单抗#

CANCER COMMUN | 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌的长期生存结果及免疫检查点抑制剂再治疗研究

2024-05-16发表于上海

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败

2022-04-04

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：信迪利单抗联合安罗替尼治疗PD-L1阳性晚期宫颈癌

2022-02-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-12-30

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：PD-1和CTLA-4双重阻断二线治疗晚期宫颈癌疗效显著

2021-12-24

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Gynecol Oncol：鳞状细胞癌抗原（SCC-Ag）是局部晚期宫颈癌患者的生存预后因素

2021-09-24

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-05-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

J Clin Oncol：未来可期| 卡瑞利珠单抗联合阿帕替尼治疗晚期宫颈癌！

2020-10-21

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Agenus的PD-1单抗Balstilimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-04-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Agenus的PD-1单抗Balstilimab联合CTLA-4单抗Zalifrelimab治疗晚期宫颈癌，获得FDA的快速通道指定

2020-03-16

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

LN-145获FDA突破性疗法认定用于治疗化疗期间或之后进展的晚期宫颈癌

2019-05-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

CLIN CANCER RES：骨骼肌损失可以作为局部晚期宫颈癌患者预后的标志

2018-11-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Lancet：贝伐单抗治疗晚期宫颈癌：GOG240研究最终分析报告

2017-10-25

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

Lancet：GOG240 III期结果公布——贝伐单抗治疗晚期宫颈癌患者的OS&AE如何？

2017-08-05

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

里程碑！欧盟批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2015-04-10

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

The Lancet Oncology：贝伐单抗有望用于治疗晚期宫颈癌

2015-02-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

罗氏Avastin再获批 **用于晚期宫颈癌的生物药物

2014-11-26

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

JCO：提高晚期宫颈癌存活率的新疗法

2014-10-01

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

FDA批准罗氏安维汀（Avastin）联合化疗治疗晚期宫颈癌

2014-08-20

ms7258648636991762 (审核中...)

前往app查看评论内容

#晚期宫颈癌#

JCO：培美曲塞联合顺铂治疗晚期宫颈癌安全有效

2014-08-08

科室
- - 订阅+
  - 更多科室
工具
服务